New hope for hard-to-treat breast cancer: triple therapy trial launches
Disease control
Not yet recruiting
This study tests a combination of three treatments—an immunotherapy drug (pembrolizumab), a targeted drug (axatilimab), and radiation—to see if they can shrink or control metastatic triple-negative breast cancer in people who have already tried immunotherapy. About 34 adults with…
Phase: PHASE2 • Sponsor: Stephen Shiao • Aim: Disease control
Last updated May 03, 2026 14:02 UTC